# CMS unveils Medicare coverage model for weight loss drugs - Endpoints News

## Metadata
| Field | Value |
|-------|-------|
| Source | Endpoints News |
| URL | https://news.google.com/rss/articles/CBMiiAFBVV95cUxQb0R3ZGJra2o5NEZNWndwM0pWWjlKTnhGZmdoN2ttaGRjcngtbUZNanZJZlJSQXc1WVdicU9sdkEyc29uOENPazg5dktCYm9SV1pIYkxaQTlrdExpNmZOeUxFaFJKX3hQdXBfN1NSOEZvdmpPbFotVGJvTU9VRHF2YzZhOVhMRXRv?oc=5&hl=en-US&gl=US&ceid=US:en |
| Scraped | 2025-12-29 12:00 |
| Category | GLP-1|Policy|Regulatory |
| Relevance | 9/10 |
| Signal | bull |

## Investment Summary
CMS proposed Medicare coverage framework for weight loss drugs signals major market expansion for obesity treatments, potentially benefiting GLP-1 manufacturers like Novo Nordisk and Eli Lilly.

## Key Entities
Centers for Medicare & Medicaid Services (CMS), Novo Nordisk, Eli Lilly

## Dollar Amounts
None mentioned

---

## Article Content

*Full content could not be extracted. Visit URL for details.*

---

#healthcare-news #glp-1|policy|regulatory #auto-scraped
